Lite Strategy, Inc. Share Price

LITS

US55279B3015

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:51:00 12/11/2026 GMT			5-day change	1st Jan Change
0.9080 ^USD	-7.83%		-6.17%	-30.90%

11-05	Lite Strategy, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2026	CI
10-13	Lite Strategy, Inc. Launches Proof of Time Public Industry Archive	CI

Valuation: Lite Strategy, Inc.

Market Cap	29.95M 27.09M 25M 22.63M 42.71M 2.82B 43.99M 300M 119M 1.51B 112M 110M 4.79B	P/E 2025	-1.03x	P/E 2026	-0.45x
Enterprise Value	24.25M 21.93M 20.24M 18.32M 34.57M 2.28B 35.61M 243M 96.55M 1.22B 91.01M 89.07M 3.88B	EV / Sales 2025	-	EV / Sales 2026	-
Free-Float	86%	Yield 2025 *	-	Yield 2026	-

* Estimated data More valuation ratios

Latest news: Lite Strategy, Inc.

11-05	Lite Strategy, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2026	CI
10-13	Lite Strategy, Inc. Launches Proof of Time Public Industry Archive	CI
09-28	Lite Strategy, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-30	Tranche Update on Lite Strategy, Inc.'s Equity Buyback Plan announced on October 29, 2025.	CI
06-29	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell Microcap Value Benchmark Index	CI
06-29	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell 3000E Index	CI
06-28	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell 3000E Value Benchmark	CI
06-28	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell Microcap Index	CI
06-17	ZK Innovations Inc. announced that it has received $1 million in funding from Lite Strategy, Inc.	CI
05-13	Tranche Update on Lite Strategy, Inc.'s Equity Buyback Plan announced on October 29, 2025.	CI
05-13	Lite Strategy, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
02-17	Lite Strategy, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
02-17	Tranche Update on Lite Strategy, Inc.'s Equity Buyback Plan announced on October 29, 2025.	CI

More news

Analysts' recommendations: Lite Strategy, Inc.

23/07/24	Laidlaw Downgrades MEI Pharma to Hold From Buy	MT
14/02/24	Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	MT
27/09/23	Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	MT
12/05/23	Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating	MT
13/02/23	Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating	MT

More recommendations

Press Releases: Lite Strategy, Inc.

11-10	Lite Strategy Reports Fiscal 2027 First Quarter Financial Results	GL
11-06	Lite Strategy : Quarterly Report for Quarter Ending September 30 (Form 10-Q)	PU
10-13	Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive	GL
09-29	Lite Strategy Reports Fiscal Year 2026 Financial Results	GL
09-10	Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York	GL

More press releases

News in other languages: Lite Strategy, Inc.

31/05/23	MÄRKTE USA/Wall Street von Wachstums- und Zinssorgen gedrückt
31/05/23	LATE BRIEFING - Unternehmen und Märkte
31/05/23	MÄRKTE USA/Wachstums- und Zinssorgen drücken Wall Street
31/05/23	MÄRKTE USA/Etwas leichter - Globale Wachstumssorgen belasten
31/05/23	MÄRKTE USA/Leichter - Anleger bleiben vorsichtig

More news

Managers and Directors: Lite Strategy, Inc.

Manager	Title	Age	Since
Justin File CEO	Chief Executive Officer	56	31/07/2024

Director	Title	Age	Since
Nick Glover BRD	Director/Board Member	57	10/06/2013
Fred Driscoll CHM	Chairman	75	31/07/2024
Justin File BRD	Director/Board Member	56	13/11/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LITE STRATEGY, INC.	-7.83%	-6.17%	-54.62%	-87.59%	29.95M
WUXI APPTEC CO., LTD.	+1.10%	+1.03%	+62.53%	+70.47%	67.53B
ARGENX SE	+1.28%	+8.71%	+13.96%	+92.70%	60.74B
LONZA GROUP AG	+0.36%	-0.95%	+20.09%	+98.45%	55.66B
BEONE MEDICINES AG	-0.65%	+8.24%	+11.04%	+110.79%	47.97B
IQVIA HOLDINGS INC.	-1.14%	+2.31%	+22.70%	+39.93%	45.24B
REVOLUTION MEDICINES, INC.	-1.92%	-0.23%	+169.25%	+802.01%	39.08B
CELLTRION, INC.	+1.21%	+4.75%	+27.30%	+52.81%	35.34B
GENMAB A/S	-0.87%	-2.89%	+79.60%	+56.33%	33.45B
INSMED INCORPORATED	-2.21%	+8.82%	-39.12%	+395.19%	26.49B
Average	-1.06%	+1.55%	+31.27%	+163.11%	41B
Weighted average by Cap.	-0.06%	+2.88%	+41.19%	+166.58%

See all sector performances

Lite Strategy, Inc. is a pharmaceutical company focused on developed and differentiated cancer therapies. The Company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kd inhibitor. CDK9 functions in cell cycle regulation, and its modulation in cancer and autoimmune diseases. It is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1). Zandelisib is an oral, once-daily, selective PI3Kd inhibitor that is developed for the treatment of indolent B-cell lymphomas. Its approach to pre-clinical drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs. It holds Litecoin (LTC) tokens as a primary asset as part of an institutional treasury. LTC is an open source, global payment network that is decentralized without any central authorities.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/11/26	US$0.9121	-7.42%	211,853
11/11/26	US$0.9851	+2.86%	107,211
10/11/26	US$0.9577	+0.86%	275,203
09/11/26	US$0.9495	-6.91%	361,234
06/11/26	US$1.020	+4.93%	233,233

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Lite Strategy, Inc.

Company calendar

1 day	-7.83%
1 week	-6.17%
Current month	-18.56%
1 month	-25.24%
3 months	-1.02%
6 months	-27.03%
Current year	-30.90%

1 week	0.9	1.05
1 month	0.9	1.27
Current year	0.69	1.65
1 year	0.69	2.08
3 years	0.69	9
5 years	0.69	71
10 years	0.69	102.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/10/26	Nick Glover	Free	Director	100,000	0.3289%
22/10/26	Justin File	Free	Chief Executive Officer	600,000	1.9732%
22/10/26	James Flynn	Free	Director	100,000	0.3289%

	2025	2026
Net sales	-	-
Net income	-15.94M -14.42M -13.31M -12.05M -22.73M -1.5B -23.42M -160M -63.49M -801M -59.84M -58.57M -2.55B	-71.15M -64.34M -59.39M -53.76M -101M -6.69B -104M -713M -283M -3.58B -267M -261M -11.38B
Net Debt	-18.01M -16.29M -15.03M -13.61M -25.68M -1.69B -26.45M -180M -71.71M -905M -67.6M -66.16M -2.88B	-5.71M -5.16M -4.76M -4.31M -8.14M -536M -8.38M -57.17M -22.72M -287M -21.42M -20.96M -913M

Lite Strategy, Inc. Share Price

Stocks

LITS

US55279B3015

Biotechnology & Medical Research

Valuation: Lite Strategy, Inc.

Chart: Lite Strategy, Inc.

Latest news: Lite Strategy, Inc.

Analysts' recommendations: Lite Strategy, Inc.

Press Releases: Lite Strategy, Inc.

News in other languages: Lite Strategy, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Lite Strategy, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Markets		Quality
Nasdaq	LITS	Delayed
London S.E.	0JW9	Delayed
CBOE	LITS	Real-time